Steuber Holger, Zentgraf Matthias, Gerlach Christof, Sotriffer Christoph A, Heine Andreas, Klebe Gerhard
Department of Pharmaceutical Chemistry, Philipps-University Marburg, Marbacher Weg 6, 35032 Marburg, Germany.
J Mol Biol. 2006 Oct 13;363(1):174-87. doi: 10.1016/j.jmb.2006.08.011. Epub 2006 Aug 9.
In structure-based drug design, accurate crystal structure determination of protein-ligand complexes is of utmost importance in order to elucidate the binding characteristics of a putative lead to a given target. It is the starting point for further design hypotheses to predict novel leads with improved properties. Often, crystal structure determination is regarded as ultimate proof for ligand binding providing detailed insight into the specific binding mode of the ligand to the protein. This widely accepted practise relies on the assumption that the crystal structure of a given protein-ligand complex is unique and independent of the protocol applied to produce the crystals. We present two examples indicating that this assumption is not generally given, even though the composition of the mother liquid for crystallisation was kept unchanged: Multiple crystal structure determinations of aldose reductase complexes obtained under varying crystallisation protocols concerning soaking and crystallisation exposure times were performed resulting in a total of 17 complete data sets and ten refined crystal structures, eight in complex with zopolrestat and two complexed with tolrestat. In the first example, a flip of a peptide bond is observed, obviously depending on the crystallisation protocol with respect to soaking and co-crystallisation conditions. This peptide flip is accompanied by a rupture of an H-bond formed to the bound ligand zopolrestat. The indicated enhanced local mobility of the complex is in agreement with the results of molecular dynamics simulations. As a second example, the aldose reductase-tolrestat complex is studied. Unexpectedly, two structures could be obtained: one with one, and a second with four inhibitor molecules bound to the protein. They are located in and near the binding pocket facilitated by crystal packing effects. Accommodation of the four ligand molecules is accompanied by pronounced shifts concerning two helices interacting with the additional ligands.
在基于结构的药物设计中,准确测定蛋白质-配体复合物的晶体结构对于阐明假定先导物与给定靶点的结合特性至关重要。它是进一步设计假设以预测具有改进特性的新型先导物的起点。通常,晶体结构测定被视为配体结合的最终证据,能深入了解配体与蛋白质的特定结合模式。这种广泛接受的做法基于这样一种假设,即给定蛋白质-配体复合物的晶体结构是独特的,且与用于制备晶体的方案无关。我们给出两个例子表明,即使结晶母液的组成保持不变,这个假设也并非普遍成立:对在不同结晶方案(涉及浸泡和结晶暴露时间)下获得的醛糖还原酶复合物进行了多次晶体结构测定,共得到17个完整数据集和10个精制晶体结构,其中8个与唑泊司他形成复合物,2个与托泊司他形成复合物。在第一个例子中,观察到一个肽键发生了翻转,显然这取决于关于浸泡和共结晶条件的结晶方案。这种肽键翻转伴随着与结合的配体唑泊司他形成的氢键的断裂。所表明的复合物局部流动性增强与分子动力学模拟结果一致。作为第二个例子,对醛糖还原酶-托泊司他复合物进行了研究。出乎意料的是,得到了两种结构:一种结构中蛋白质结合了一个抑制剂分子,另一种结构中结合了四个抑制剂分子。它们位于由晶体堆积效应促成的结合口袋内及附近。四个配体分子的容纳伴随着与额外配体相互作用的两个螺旋发生明显位移。